关注
Rosa Nadal
Rosa Nadal
在 nih.gov 的电子邮件经过验证
标题
引用次数
引用次数
年份
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer
ES Antonarakis, C Lu, H Wang, B Luber, M Nakazawa, JC Roeser, ...
New England Journal of Medicine 371 (11), 1028-1038, 2014
28382014
Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer
ES Antonarakis, C Lu, B Luber, H Wang, Y Chen, M Nakazawa, R Nadal, ...
JAMA oncology 1 (5), 582-591, 2015
6842015
PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer
SP Rowe, KJ Macura, E Mena, AL Blackford, R Nadal, ES Antonarakis, ...
Molecular imaging and biology 18, 411-419, 2016
2622016
Small cell carcinoma of the prostate
R Nadal, M Schweizer, ON Kryvenko, JI Epstein, MA Eisenberger
Nature Reviews Urology 11 (4), 213-219, 2014
2572014
Management of metastatic bladder cancer
R Nadal, J Bellmunt
Cancer treatment reviews 76, 10-21, 2019
2332019
Short-term natural weathering of MSWI bottom ash
JM Chimenos, AI Fernández, R Nadal, F Espiell
Journal of Hazardous Materials 79 (3), 287-299, 2000
1722000
Biomarkers characterization of circulating tumour cells in breast cancer patients
R Nadal, A Fernandez, P Sanchez-Rovira, M Salido, M Rodríguez, ...
Breast Cancer Research 14, 1-12, 2012
1252012
CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy
R Nadal, FG Ortega, M Salido, JA Lorente, M Rodríguez‐Rivera, ...
International journal of cancer 133 (10), 2398-2407, 2013
1192013
Comparison of prostate-specific membrane antigen–based 18F-DCFBC PET/CT to conventional imaging modalities for detection of hormone-naïve and castration-resistant metastatic …
SP Rowe, KJ Macura, A Ciarallo, E Mena, A Blackford, R Nadal, ...
Journal of Nuclear Medicine 57 (1), 46-53, 2016
1162016
Phase I study of cabozantinib and nivolumab alone or with ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors
AB Apolo, R Nadal, DM Girardi, SA Niglio, L Ley, LM Cordes, ...
Journal of Clinical Oncology 38 (31), 3672-3684, 2020
1082020
Clinical activity of enzalutamide versus docetaxel in men with castration‐resistant prostate cancer progressing after abiraterone
DL Suzman, B Luber, MT Schweizer, R Nadal, ES Antonarakis
The Prostate 74 (13), 1278-1285, 2014
1082014
Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
HH Cheng, R Gulati, A Azad, R Nadal, P Twardowski, UN Vaishampayan, ...
Prostate cancer and prostatic diseases 18 (2), 122-127, 2015
1002015
EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer
MJ Serrano, FG Ortega, MJ Alvarez-Cubero, R Nadal, P Sanchez-Rovira, ...
Oncotarget 5 (17), 7486, 2014
902014
Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration‐resistant prostate cancer: a retrospective study
BL Maughan, B Luber, R Nadal, ES Antonarakis
The Prostate 77 (1), 33-40, 2017
842017
Bipolar androgen therapy for men with androgen ablation naive prostate cancer: results from the phase II BATMAN study
MT Schweizer, H Wang, B Luber, R Nadal, A Spitz, DM Rosen, H Cao, ...
The Prostate 76 (13), 1218-1226, 2016
802016
Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)–tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients …
R Nadal, A Amin, DM Geynisman, MH Voss, M Weinstock, J Doyle, ...
Annals of Oncology 27 (7), 1304-1311, 2016
762016
Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC)(RADVAX RCC).
HJ Hammers, D Vonmerveldt, C Ahn, RM Nadal, CG Drake, MR Folkert, ...
Journal of Clinical Oncology 38 (6_suppl), 614-614, 2020
752020
Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer
X Nogues, S Servitja, MJ Peña, D Prieto-Alhambra, R Nadal, ...
Maturitas 66 (3), 291-297, 2010
722010
Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial
AB Apolo, R Nadal, Y Tomita, NN Davarpanah, LM Cordes, SM Steinberg, ...
The Lancet Oncology 21 (8), 1099-1109, 2020
682020
Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial …
RM Nadal, A Mortazavi, M Stein, SK Pal, NN Davarpanah, HL Parnes, ...
Journal of Clinical Oncology 36 (6_suppl), 515-515, 2018
682018
系统目前无法执行此操作,请稍后再试。
文章 1–20